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The Second International Study of Infarct Survival (ISIS-2)
(1) established that aspirin in a dose of 160 mg/day (the first
dose chewed at the time of randomization) added to the
reduction in mortality achieved with streptokinase in the
treatment of acute myocardial infarction. Because the com-
bination of aspirin and streptokinase resulted in a signifi-
cantly lesser incidence of recurrent ischemia than that
achieved with streptokinase alone, the implication has been
that the platelet inhibitor acted by lessening the incidence of
reocclusion. Although this is a reasonable conclusion, angio-
graphic confirmation in randomized trials has been limited
by a lack of statistical power. Thus, Verheugt et al. (2)
randomized 50 patients (24 to aspirin, 100 mg/day; 26 to
placebo) after they had received 1.5 million U of streptoki-
nase and subcutaneously administered heparin within 4 h of
the onset of anterior wall myocardial infarction. At angiog-
raphy within 6 weeks (average 28 days) after thrombolysis, 1
01%) of 9 aspirin-treated patients and 12 (75%) of 16
placebo-treated patients demonstrated occlusion of the left
anterior descending artery. Nine (37.5%) of the 24 aspirin-
treated patients developed unstable angina or recurrent
myocardial infarction compared with 12 (46%) of the 26
placebo-treated patients during a 3-month follow-up period.
The randomized Heparin-Aspirin Reperfusion Trial
(HART) (3) compared early intravenous heparin with oral
aspirin, 80 mg/day, as adjunctive treatment to thrombolysis
with recombinant tissue-type plasminogen activator (rt-PA).
The primary end point was the patency rate after 7 to 24 h,
but a secondary end point was reocclusion between days
1 and 7. Although the initial patency rate was higher with
"Editorials published in Journal of the American College of Cardiology
reflect the views of the authors and do not necessarily represent the views of
JACC or the American College of Cardiology.
From the Department of Medicine, Temple University School of Medi-
cine, Philadelphia. Pennsylvania and tHematology Unit, Department of
Medicine, University of Rochester School of Medicine and Dentistry, Roch-
ester, New York. This study was supported in part by Grant HL-306l6 from
the National Heart, Lung, and Blood Institute, National Institutes of Health,
Bethesda, Maryland.
Address for reprints: Sol Sherry, MD, 4th Floor SFC, Temple University
School of Medicine, 3400 North Broad Street, Philadelphia, Pennsylvania
19140.
©1992 by the American College of Cardiology
JACC Vol. 19, No.3
March I, 1992:678-80
heparin, 7 02%) of 60 patients in the heparin-treated group
exhibited reocclusion as compared with 2 (5%) of 38 in the
aspirin-treated group. Recurrent ischemic episodes were
observed in 8 (8%) of the 106 patients originally randomized
to heparin and in only 2(2%) of the 99 patients given aspirin.
Although these two studies supported the concept that the
action of aspirin was to prevent reocclusion of vessels made
patent by thrombolytic therapy, neither provided convincing
evidence, considering the small number of end points.
The present study. The study by Roux et al. (4) in this
issue of the Journal overcomes the lack of statistical power
of small studies by using the technique of meta-analysis, to
combine the data from all studies reported from 1980 to 1990
that allowed for an analysis of reocclusion rates. The studies
included provided angiographic evidence of vessel patency
at 90 min after the onset of therapy and a follow-up angio-
gram before hospital discharge, as well as data on the
incidence of recurrent ischemia in patients treated with
heparin and either streptokinase or rt·PA with or without
aspirin. The analysis included 32 studies 09 randomized, 13
nonrandomized) and involved 3,209 patients treated with
and 1,721 treated without aspirin. A total of 932 patients
were available for analysis of reocclusion and 3,968 patients
for analysis of recurrent ischemia. The daily dose of aspirin
varied from 80 to 1,000 mg.
Using this approach, the authors (4) provide evidence
based on reasonable confidence limits and p values of 0.001
that therapy with aspirin and heparin dramatically lowers the
incidence of reocclusion and recurrent ischemia, is associ-
ated with a trend toward a lower mortality rate (reduction of
mortality and of recurrent ischemia had been established
previously [1]) and that a similar effect is evident for both
streptokinase and rt·PA.
The study is important because it provides the statistical
power to establish the mechanism of action of aspirin in the
treatment of acute myocardial infarction (namely, the pre-
vention of reocclusion). These results mesh neatly with the
anticipated action of aspirin-to limit platelet aggregation-
the most likely initiating mechanism for rethrombosis after
thrombolytic therapy at the site of vascular injury or residual
unlysed thrombus. Although there is little reason not to
accept its conclusions, the study can be characterized by a
remark made more than a half-century ago by Mansfield
Clark, the noted Johns Hopkins biochemist (Tillett WS.
Personal communication). With respect to physical chem-
ists, Clark commented that they made "exquisite measure-
ments on shockingly impure preparations." The same can be
said about this study. The authors recognize the multiplicity
of study designs that are included in their analysis and admit
that, although their conclusions are justified qualitatively,
the quantitative aspects are not precise.
Limitations. There are some other problems with the
study. First is the assumption that reocclusion rates can be
measured by determining angiographically whether vessels
opened at 90 min have reoccluded by the time of hospital
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discharge (or earlier). The 90-min patency rate popularized
by the Thrombolysis in Myocardial Infarction (TIM!) Phase
I trial (5) is a measure of the speed of lysis of thrombus (5),
but it does not reflect the total incidence of induced patency
(6). Patency rates increase progressively, as clearly shown
by Hogg (7), Pacouret (8) and Anderson (9) and their
coworkers in their studies of streptokinase and anistreplase
(APSAC); they are much higher at 24 h than at 90 min (6-9).
Also, there is evidence (6) that patency rates achieved with
rt-PA, streptokinase and APSAC probably become equiva-
lent at 3 h. Furthermore, the speed with which vessels
become patent is affected by the time elapsed from symptom
onset to the start of therapy (4-6); thus, the longer the
interval between symptoms and therapy with streptokinase,
APSAC or urokinase, the fewer will be the number of
vessels open at 90 min that subsequently open. Thus, if
angiographic measurements made before hospital discharge
are limited to vessels patent at 90 min, they will not reflect
data on patency or reocclusion of vessels that open after
90 min. Additionally, there are two distinct periods of
reocclusion-early reocclusion, based on the hypercoagula-
bility of the blood induced by thrombolytic therapy (10), and
late reocclusion, which appears to be slowly progressive
once a relatively stable state of vessel patency (usually 24 h
[11]) has been reached. Neither of these points is addressed
in this study, thus limiting an adequate evaluation of the
effects of aspirin on reocclusion rates.
The second problem relates to the conclusion that aspirin
strikingly reduces reocclusion in patients treated with rt-PA
although the aspirin group received 150 mg of rt-PA,
whereas the group without aspirin received only 74 mg of
rt-PA. After the work of Gold et al. (12) had emphasized the
high rate ofrethrombosis after rt-PA therapy, evidence was
presented (13) that using a longer duration of therapy
(6 rather than 4 h) and a higher dose of rt-PA (150 rather than
80 mg of the double-stranded rt-PA) reduced rethrombosis
by producing more extensive thrombolysis, better flow
rates, more fibrinogen degradation and more stable vessel
patency. Unfortunately, this regimen caused an unaccept-
able incidence of cerebral bleeding (14). Thus, the observa-
tions made in the study of Roux et al. (4) on the effect of
aspirin on reocclusion rates with different regimens of rt-PA
are meaningless and cannot be used to support the conclu-
sion that the effects of aspirin are similar both for streptoki-
nase and rt-PA therapy, although this is likely.
Third and most important, the report implies that the
reduction in reocclusion rates is dependent on the adjunctive
use of heparin as well, an aspect not addressed in this study
or as yet adequately answered by comparative trials. Indeed,
this aspect raises many fundamental questions. Is aspirin
necessary in the presence of early and maintained intrave-
nous heparin therapy? Is heparin necessary in the presence
of adequate amounts of aspirin (160 to 325 mg given imme-
diately and each day thereafter)? Is the combination of
heparin and aspirin more effective than either alone? Is the
answer to these questions the same for rt-PA, streptokinase
and APSAC? Are these adjunctive agents effective for both
early and late reocclusion?
Conclusions. Answers to these questions are not yet
available, but studies in progress such as Global Utilization
of Streptokinase and t-PA for Occluded Coronary Arteries
trial (GUSTO) may provide further information. On the basis
of different pharmacologic states produced by each agent, as
well as the observations made in clinical trials, we predict
that 1) aspirin given immediately in a dose of:2: 160 mg/day is
necessary (even in the presence of heparin) to reduce early
and late reocclusions, but when it is given in smaller daily
doses (15-19) its effect is primarily to reduce late reocclusion
(3). 2) Heparin is probably not necessary with streptokinase
and APSAC because the hypercoagulable state produced by
these agents is rapidly replaced by a hypocoagulable state,
but it is necessary with rt-PA therapy in which hypercoagu-
lability persists for a considerable period of time. 3) Heparin
in the presence of adequate amounts of aspirin is likely to
add an additional but modest benefit (1,20). However, when
no aspirin (21) or inadequate amounts of aspirin (3) are used,
heparin is more effective than when administered in the
presence of adequate aspirin therapy (22). 4) Immediate and
intravenous heparin and immediate and daily aspirin therapy
as practiced in U.S. hospitals will show similar results for
streptokinase and'rt-PA therapy in mortality reduction but
will be accompanied by a significant increase in serious
bleeding. 5) Different factors appear to be involved in early
(hypercoagulable state) and late reocclusions (high degree of
residual stenosis, underlying vascular lesion, residual throm-
bus). Thus, the adjunctive therapies required to control early
and late occlusions ultimately may prove to be somewhat
different.
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